Page last updated: 2024-09-04

pixantrone and Neutropenia

pixantrone has been researched along with Neutropenia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bregni, M; Bugli, A; Mitterer, M; Musuraca, G; Piazza, F; Pinto, A; Spione, M; Zinzani, PL	1
Borchmann, P; Camboni, G; Engert, A; Gisselbrecht, C; Günther, H; Harousseau, JL; Morschhauser, F; Parry, A; Pfreundschuh, DM; Rudolph, C; Schnell, R; Wilhelm, M	1
El-Helw, LM; Hancock, BW	1
Bernareggi, A; Borchmann, P; Camboni, GM; Diehl, V; Engert, A; Hübel, K; Knippertz, R; Schnell, R; Schulz, A; Staak, JO; Staib, P	1

Reviews

1 review(s) available for pixantrone and Neutropenia

Article	Year
Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:10 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Neutropenia; Thrombocytopenia; Topoisomerase II Inhibitors	2007

Trials

2 trial(s) available for pixantrone and Neutropenia

Article	Year
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica, 2003, Volume: 88, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Recurrence; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome	2003
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Treatment Outcome	2001

Article

Year

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

Haematologica, 2003, Volume: 88, Issue:8

Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Recurrence; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome

2003

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Treatment Outcome

2001

Other Studies

1 other study(ies) available for pixantrone and Neutropenia

Article	Year
Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry. Acta haematologica, 2021, Volume: 144, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Female; Genetic Diseases, X-Linked; Humans; Isoquinolines; Italy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Registries; Retrospective Studies; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome	2021

Article

Year

Effectiveness and Safety of Pixantrone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Every-Day Clinical Practice: The Italian Cohort of the PIXA Registry.

Acta haematologica, 2021, Volume: 144, Issue:3

Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Female; Genetic Diseases, X-Linked; Humans; Isoquinolines; Italy; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neutropenia; Registries; Retrospective Studies; Thrombocytopenia; Topoisomerase II Inhibitors; Treatment Outcome

2021